IMI announces nomination of Ron Henriksen to Board of Directors

IMI announces nomination of Ron Henriksen to Board of Directors



TORONTO, April 13  /PRNewswire-FirstCall/ -- IMI International Medical
Innovations Inc. (TSX: IMI, Amex: IME) today announced that Ron Henriksen has
agreed to join the company's Board of Directors, pending shareholder approval at
the upcoming annual shareholders meeting to be held on June 16, 2004. In the
interim, IMI has engaged Mr. Henriksen as a business consultant.

"IMI is already benefiting from Ron's wealth of industry knowledge and
international perspective. He has proven expertise in the U.S. and global
marketplaces, having completed more than 65 licensing, research collaboration
and acquisition agreements with a variety of partners," said Dr. Brent Norton,
President and Chief Executive Officer. "Ron's guidance and counsel will
certainly be invaluable as we continue to establish IMI as a leader in the field
of predictive medicine."

Mr. Henriksen brings more than 30 years of experience in the healthcare field,
working in the pharmaceutical, biotechnology, consulting and venture capital
industries. He is currently Chief Investment Officer of Indianapolis-based
Twilight Ventures, LLC, which is a venture capital firm investing exclusively in
life science companies. Prior to joining Twilight Ventures, he was President of
ARTI (Indiana University's Advanced Research & Technology Institute) from 1998
until 2002. Mr. Henriksen served Eli Lilly and Company (NYSE:LLY) for more than
two decades in a variety of senior managerial and executive positions in
business development, marketing and finance, where he worked closely with
outside biotechnology, medical device and diagnostic companies.

In addition, Mr. Henriksen has acted as a consultant to several medical device
and biotechnology companies, providing breadth and depth of expertise in
business development, financing and general management. In October 1993,
BioPeople Magazine selected him as the "number one business development
executive in the world".

"IMI is an innovative and growing company with a novel approach to identifying
better predictors of cardiovascular disease and cancer," said Mr. Henriksen. "I
look forward to working with the IMI team as the company brings its unique
predictive medicine products to market."

Mr. Henriksen currently serves on the board of directors of QLT, Inc. (TSX: QLT;
NASDAQ: QLTI), MacroPore Biosurgery, Inc. (XETRA: XMP), TGN Biotech Inc.,
CyberLearning Labs, Inc. and BioStorage Technologies. He received a Bachelor of
Science degree in Industrial Administration at Iowa State University and a
Master of Business Administration (with distinction) degree from the Harvard
Business School.

About IMI

IMI is a world leader in predictive medicine, dedicated to developing rapid,
non-invasive tests for the early detection of life-threatening diseases,
particularly cardiovascular disease and cancer. The company's head office is
located in Toronto, and its research and product development facility is at
McMaster University in Hamilton, Ontario. For further information, please visit
the company's website at http://www.imimedical.com/.

This release contains forward-looking statements that reflect the company's
current expectation regarding future events. The forward-looking statements
involve risk and uncertainties. Actual events could differ materially from those
projected herein and depend on a number of factors including, but not limited
to, changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process, establishment
of corporate alliances and other risks detailed from time to time in the
company's quarterly, annual and other regulatory filings. 

DATASOURCE: IMI International Medical Innovations Inc.



CONTACT: Sarah Borg-Olivier, Director, Communications,

T: [phone], 

Copyright